|
Market Closed -
NSE India S.E.
07:05:10 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 1,801.00 INR | -0.86% |
|
-2.64% | +4.73% |
| Market Cap | 4,321B 44.95B 39.94B 37.28B 33.98B 64.08B 64.67B 451B 175B 2,209B 169B 165B 7,090B | P/E 2027 * |
33.2x | P/E 2028 * | 28.1x |
|---|---|---|---|---|---|
| Enterprise Value | 4,051B 42.13B 37.44B 34.94B 31.85B 60.06B 60.62B 423B 164B 2,071B 158B 155B 6,646B | EV / Sales 2027 * |
6.22x | EV / Sales 2028 * | 5.46x |
| Free-Float |
44.39% | Yield 2027 * |
0.95% | Yield 2028 * | 1.11% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.86% | ||
| 1 week | -2.64% | ||
| Current month | -0.86% | ||
| 1 month | -6.64% | ||
| 3 months | -3.49% | ||
| 6 months | +4.19% | ||
| Current year | +4.73% |
| 1 week | 1,792.6 |  | 1,865 |
| 1 month | 1,792.6 | | 1,936.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,583.7 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 2025-08-31 | |
| Director of Finance/CFO | 58 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 2025-08-31 | |
| Director/Board Member | 73 | 2018-05-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.86% | -2.64% | +10.07% | +55.44% | 44.88B | |
| -0.61% | -3.43% | +39.40% | +112.31% | 1,025B | |
| -1.02% | -5.60% | +37.67% | +65.02% | 623B | |
| +1.11% | -0.58% | +11.10% | +77.28% | 459B | |
| +0.34% | -3.01% | +61.21% | +40.71% | 355B | |
| -0.95% | -4.87% | +22.46% | +38.03% | 336B | |
| -1.46% | -2.20% | +11.84% | +23.94% | 270B | |
| -1.35% | -4.27% | -4.55% | +6.92% | 247B | |
| -1.04% | -2.79% | +35.52% | +51.34% | 220B | |
| -1.87% | -4.10% | +30.92% | +95.33% | 183B | |
| Average | -0.71% | -1.97% | +25.56% | +56.63% | 376.31B | |
| Weighted average by Cap. | -0.47% | -2.11% | +30.35% | +68.50% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.77B 6.02B 5.62B 5.12B 9.66B 9.75B 67.97B 26.34B 333B 25.43B 24.88B 1,068B | 730B 7.59B 6.74B 6.29B 5.74B 10.82B 10.92B 76.16B 29.51B 373B 28.49B 27.87B 1,197B |
| Net income | 129B 1.35B 1.2B 1.12B 1.02B 1.92B 1.94B 13.5B 5.23B 66.13B 5.05B 4.94B 212B | 154B 1.6B 1.42B 1.32B 1.21B 2.28B 2.3B 16.03B 6.21B 78.51B 6B 5.87B 252B |
| Net Debt | -271B -2.82B -2.5B -2.33B -2.13B -4.01B -4.05B -28.26B -10.95B -138B -10.57B -10.34B -444B | -338B -3.52B -3.13B -2.92B -2.66B -5.02B -5.07B -35.33B -13.69B -173B -13.22B -12.93B -555B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-01 | ₹1,801.00 | -0.86% | 2,314,700 |
| 26-09-30 | ₹1,816.60 | -2.60% | 2,401,495 |
| 26-09-29 | ₹1,865.00 | +1.47% | 3,083,083 |
| 26-09-28 | ₹1,838.00 | -0.77% | 947,719 |
| 26-09-25 | ₹1,852.20 | +0.12% | 683,246 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
